FPI 2071
Alternative Names: FPI-2071Latest Information Update: 10 Jun 2024
Price :
$50 *
At a glance
- Originator Fusion Pharmaceuticals
- Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 04 Jun 2024 Fusion Pharmaceuticals has been acquired by AstraZeneca
- 11 Oct 2023 Preclinical trials in Cancer in Canada (IV) prior to October 2023
- 11 Oct 2023 Pharmacokinetics data from a preclinical trial in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)